Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2008

View Archived Issues

Further data on pregabalin efficacy in generalized anxiety disorder reported

Adenosine A3 receptor expression correlated with responses to CF-101 in RA patients

QUATRx reports results from two phase I clinical studies of sobetirome

Novel compounds for cancer treatment disclosed in recent patent literature

Genetic variation in drug transporter ABCB1 is linked to antidepressant efficacy

Sinclair's new herpes simplex treatment registered in the E.U.

Viventia Biotech to consider strategic alternatives

Transtec provides a safe alternative in opioid treatment

Recent Novartis patents describe novel agents for asthma therapy

M's Science initiates European phase II stroke recovery study

Novel treatment options for septic shock imparted in recent Abbott and Takeda patents

FDA accepts BLA filing for Dysport in cervical dystonia

AMAG provides additional information on clinical development program for ferumoxytol

CYT-387 shows encouraging ex vivo results in patients with myeloproliferative disorders

Oncolytics meets criteria to proceed to full enrollment in phase II clinical trial of Reolysin

Millennium and Harvard Medical School sign agreement for protein homeostasis research

Abbott is to invest up to USD 40 million in Ibis Biosciences

Kiadis reports successful completion of phase II clinical trial of Rhitol for GvHD

FDA grants priority review for Schering-Plough's Peg-IFN for stage III melanoma

Preclinical antitumor profile of proteasome inhibitor CEP-18770 reported

AVEO initiates phase Ib clinical trial of AV-951 in metastatic renal cell carcinoma

Pfizer obtains Japanese approval for Revatio in pulmonary hypertension

TargeGen commences clinical trial of TG-101348 in myeloproliferative disease

MediciNova's MN-166 reduces persistent black hole formation in MS

Studies show safety and efficacy of elvucitabine in HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...